MX2009011784A - Composicion para el suminitro transmucosal de polipeptidos. - Google Patents
Composicion para el suminitro transmucosal de polipeptidos.Info
- Publication number
- MX2009011784A MX2009011784A MX2009011784A MX2009011784A MX2009011784A MX 2009011784 A MX2009011784 A MX 2009011784A MX 2009011784 A MX2009011784 A MX 2009011784A MX 2009011784 A MX2009011784 A MX 2009011784A MX 2009011784 A MX2009011784 A MX 2009011784A
- Authority
- MX
- Mexico
- Prior art keywords
- biologically active
- transmucosal
- active polypeptide
- polypeptides
- dosage form
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 7
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 238000010521 absorption reaction Methods 0.000 abstract 3
- 239000002552 dosage form Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 239000003833 bile salt Substances 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 210000004400 mucous membrane Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000007909 solid dosage form Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
Abstract
La invención descrita en la presente, proporciona una forma de dosificación oral transmucosal sólida que mejora la permeación transmucosal de polipéptidos biológicamente activos a través del tejido mucosal oral y proporciona un inicio terapéutico eficaz relativamente rápido de los mismos. Las formas de dosificación, preparadas de acuerdo con la invención, pueden mejorar en el receptor la absorción transmucosal de polipéptidos en concentraciones en suero terapéuticas. La invención proporciona una forma de dosificación sólida para la absorción transmucosal oral de un polipéptido biológicamente activo, en donde la forma de dosificación comprende una composición farmacéutica que comprende: un polipéptido terapéuticamente activo; una sal biliar; y un componente excipiente efervescente, que puede comprender un par efervescente y opcionalmente una sustancia que ajusta el pH. La invención incluye un método para administrar un polipéptido biológicamente activo, así como un método para mejorar la absorción transmucosal de un polipéptido biológicamente activo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92700607P | 2007-05-01 | 2007-05-01 | |
| PCT/US2008/005655 WO2008137054A2 (en) | 2007-05-01 | 2008-05-01 | Composition for transmucosal delivery of polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009011784A true MX2009011784A (es) | 2009-11-13 |
Family
ID=39944167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009011784A MX2009011784A (es) | 2007-05-01 | 2008-05-01 | Composicion para el suminitro transmucosal de polipeptidos. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20100111902A1 (es) |
| EP (2) | EP2155229B1 (es) |
| JP (1) | JP5611033B2 (es) |
| CN (1) | CN101674843A (es) |
| AT (1) | ATE495753T1 (es) |
| AU (1) | AU2008248228B2 (es) |
| CA (1) | CA2685853A1 (es) |
| CY (1) | CY1111422T1 (es) |
| DE (1) | DE602008004656D1 (es) |
| DK (1) | DK2155229T3 (es) |
| ES (1) | ES2359875T3 (es) |
| HR (1) | HRP20110273T1 (es) |
| IL (1) | IL201563A (es) |
| MX (1) | MX2009011784A (es) |
| NZ (1) | NZ580967A (es) |
| PL (1) | PL2155229T3 (es) |
| SI (1) | SI2155229T1 (es) |
| WO (1) | WO2008137054A2 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2504019A2 (en) | 2009-11-25 | 2012-10-03 | ArisGen SA | Mucosal delivery composition comprising a peptide complexed with a crown compound and/or a counter ion |
| RU2519099C1 (ru) * | 2012-11-08 | 2014-06-10 | Федеральное государственное бюджетное учреждение науки Ордена Трудового Красного Знамени Институт нефтехимического синтеза им. А.В. Топчиева Российской академии наук (ИНХС РАН) | Фармацевтическая композиция |
| CN104667254A (zh) * | 2013-11-29 | 2015-06-03 | 中国科学院兰州化学物理研究所 | 一种鱼低聚肽泡腾片及其制备方法 |
| CN104840958B (zh) * | 2015-05-28 | 2018-03-30 | 广州帝奇医药技术有限公司 | 人工粘膜组合物及其制备方法和应用 |
| IT201700120081A1 (it) | 2017-10-23 | 2019-04-23 | Biofarma S P A | Dispositivo e metodo per la somministrazione orale di principi attivi |
| WO2019082221A2 (en) * | 2017-10-23 | 2019-05-02 | Biofarma S.P.A. | DEVICE AND METHOD FOR ORAL ADMINISTRATION OF ACTIVE PRINCIPLES |
| KR20200132852A (ko) | 2018-01-23 | 2020-11-25 | 길라 테라퓨틱스, 인코포레이티드 | 펩티드 yy 약학적 제형, 조성물, 및 방법 |
| WO2020236802A1 (en) * | 2019-05-20 | 2020-11-26 | Poviva Corp. | Compositions comprising biologically active agents and bile salts |
| US20220249465A1 (en) * | 2019-05-31 | 2022-08-11 | Primo Pharmatech Llc | Unit dosage form for transmucosal drug delivery of an active pharmaceutical ingredient |
| US11291701B1 (en) * | 2021-02-04 | 2022-04-05 | Seed Edibles | Orally disintegrating, sublingual and buccal formulations |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US142197A (en) * | 1873-08-26 | Improvement in fanning-mills | ||
| US2735304A (en) | 1956-02-21 | toppfb haw | ||
| US142198A (en) * | 1873-08-26 | Improvement in windmills | ||
| US169989A (en) * | 1875-11-16 | Improvement in iron fences | ||
| US2613204A (en) | 1952-10-07 | of urea | ||
| US163838A (en) * | 1875-06-01 | Improvement in mariners compasses | ||
| GB697914A (en) | 1949-10-24 | 1953-09-30 | Ruf Buchhaltung Ag | Improvements in and relating to a sheet feeding and guiding device for a typewriter |
| BE502283A (es) | 1950-03-31 | |||
| US4849227A (en) * | 1986-03-21 | 1989-07-18 | Eurasiam Laboratories, Inc. | Pharmaceutical compositions |
| JP2911496B2 (ja) | 1989-09-11 | 1999-06-23 | 帝國製薬株式会社 | 生理活性ポリペプチド含有高吸収性経膣剤 |
| US5178878A (en) | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
| US5482706A (en) | 1992-04-17 | 1996-01-09 | Takeda Chemical Industries, Ltd. | Transmucosal therapeutic composition |
| US5503846A (en) | 1993-03-17 | 1996-04-02 | Cima Labs, Inc. | Base coated acid particles and effervescent formulation incorporating same |
| US5766620A (en) | 1995-10-23 | 1998-06-16 | Theratech, Inc. | Buccal delivery of glucagon-like insulinotropic peptides |
| JP4037464B2 (ja) | 1997-04-01 | 2008-01-23 | シーマ・ラブス・インコーポレイテッド | ブリスタパッケージ及びパッケージタブレット |
| US6024981A (en) | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
| US6974590B2 (en) | 1998-03-27 | 2005-12-13 | Cima Labs Inc. | Sublingual buccal effervescent |
| US6200604B1 (en) * | 1998-03-27 | 2001-03-13 | Cima Labs Inc. | Sublingual buccal effervescent |
| US20050158408A1 (en) * | 1998-07-24 | 2005-07-21 | Yoo Seo H. | Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof |
| US6210699B1 (en) * | 1999-04-01 | 2001-04-03 | Watson Pharmaceuticals, Inc. | Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity |
| JP5244318B2 (ja) | 2003-12-31 | 2013-07-24 | シーマ・ラブス、インコーポレイテッド | 発泡性経口アヘン薬投薬形態およびアヘン薬の投与方法 |
| WO2005065317A2 (en) | 2003-12-31 | 2005-07-21 | Cima Labs Inc. | Effervescent oral fentanyl dosage form |
| BRPI0418228B8 (pt) | 2003-12-31 | 2021-05-25 | Cima Labs Inc | forma de dosagem, e, método de preparação de um tablete para administração bucal, gengival ou sublingual de fentanil |
-
2008
- 2008-05-01 CA CA002685853A patent/CA2685853A1/en not_active Abandoned
- 2008-05-01 PL PL08754187T patent/PL2155229T3/pl unknown
- 2008-05-01 ES ES08754187T patent/ES2359875T3/es active Active
- 2008-05-01 WO PCT/US2008/005655 patent/WO2008137054A2/en not_active Ceased
- 2008-05-01 DE DE602008004656T patent/DE602008004656D1/de active Active
- 2008-05-01 EP EP08754187A patent/EP2155229B1/en not_active Not-in-force
- 2008-05-01 AU AU2008248228A patent/AU2008248228B2/en not_active Ceased
- 2008-05-01 NZ NZ580967A patent/NZ580967A/en unknown
- 2008-05-01 MX MX2009011784A patent/MX2009011784A/es active IP Right Grant
- 2008-05-01 DK DK08754187.6T patent/DK2155229T3/da active
- 2008-05-01 EP EP11151281A patent/EP2316472A1/en not_active Withdrawn
- 2008-05-01 AT AT08754187T patent/ATE495753T1/de active
- 2008-05-01 HR HR20110273T patent/HRP20110273T1/hr unknown
- 2008-05-01 CN CN200880014387A patent/CN101674843A/zh active Pending
- 2008-05-01 SI SI200830213T patent/SI2155229T1/sl unknown
- 2008-05-01 JP JP2010506325A patent/JP5611033B2/ja not_active Expired - Fee Related
-
2009
- 2009-10-15 IL IL201563A patent/IL201563A/en not_active IP Right Cessation
- 2009-10-30 US US12/609,998 patent/US20100111902A1/en not_active Abandoned
-
2011
- 2011-04-15 CY CY20111100380T patent/CY1111422T1/el unknown
- 2011-11-22 US US13/302,868 patent/US20120076757A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SI2155229T1 (sl) | 2011-05-31 |
| HRP20110273T1 (hr) | 2011-05-31 |
| JP2010526071A (ja) | 2010-07-29 |
| EP2316472A1 (en) | 2011-05-04 |
| EP2155229A2 (en) | 2010-02-24 |
| IL201563A (en) | 2013-05-30 |
| EP2155229B1 (en) | 2011-01-19 |
| DK2155229T3 (da) | 2011-05-09 |
| AU2008248228B2 (en) | 2012-10-18 |
| CA2685853A1 (en) | 2008-11-13 |
| DE602008004656D1 (de) | 2011-03-03 |
| CY1111422T1 (el) | 2015-08-05 |
| AU2008248228A1 (en) | 2008-11-13 |
| ATE495753T1 (de) | 2011-02-15 |
| PL2155229T3 (pl) | 2011-06-30 |
| CN101674843A (zh) | 2010-03-17 |
| US20120076757A1 (en) | 2012-03-29 |
| NZ580967A (en) | 2012-04-27 |
| JP5611033B2 (ja) | 2014-10-22 |
| HK1141444A1 (en) | 2010-11-12 |
| WO2008137054A2 (en) | 2008-11-13 |
| IL201563A0 (en) | 2010-05-31 |
| ES2359875T3 (es) | 2011-05-27 |
| WO2008137054A3 (en) | 2009-06-04 |
| US20100111902A1 (en) | 2010-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1111422T1 (el) | Συνθεση για διαβλεννογονικη παραδοση πολυπεπτιδιων | |
| MX2009002314A (es) | Composiciones farmaceuticas que comprenden hgh para suministro oral. | |
| UA94734C2 (ru) | ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ | |
| IL176449A0 (en) | Generally linear effervescent oral fentanyl dosage form and methods of administering | |
| WO2005065317A3 (en) | Effervescent oral fentanyl dosage form | |
| EA201070827A1 (ru) | Способы и композиции для перорального введения белковых и пептидных терапевтических средств | |
| IL196425A0 (en) | Pharmaceutical compositions containing ibuprofen and famotidine | |
| IL172783A0 (en) | Rasgap derived peptide for selectively killing cancer cells | |
| WO2005081742A3 (en) | Testosterone oral dosage formulations and associated methods | |
| DE602008006700D1 (es) | ||
| IL289245B1 (en) | PEG-conjugated cystathionine beta synthase for enzyme therapy for the treatment of homocystinuria | |
| CO5640120A2 (es) | Formulacion y metodods para el tratamiento de trombocitemia | |
| WO2007061829A3 (en) | Pharmaceutical composition | |
| NO20055209D0 (no) | Peptabody for cancerbehandling | |
| UA92011C2 (ru) | Облатка, содержащая стероидные гормоны | |
| NO20024673L (no) | Farmasöytisk sammensetning med kontrollert frigivning for oral anvendelse inneholdende midodrin og/eller desglymidodrin | |
| UA97096C2 (ru) | Выделенное антитело, которое специфически связывает рецептор-2 trail (tr-2) | |
| EP1583545A4 (en) | PHARMACEUTICAL COMPOSITION FOR IMPROVED ADMINISTRATION OF PEPTIDES OF HIV GP41 AND ITS THERAPEUTIC USE | |
| IL179177A (en) | A pharmaceutical product including acyclovir and delivery compound, dosage unit, use of acyclovir in the preparation of the pharmaceutical product, use of the pharmaceutical product in the preparation of a drug and a method for the preparation of the pharmaceutical product | |
| TW200611697A (en) | Generally linear effervescent oral fentanyl dosage form and methods of administering | |
| WO2004014318A3 (en) | Levothyroxine compositions and methods | |
| WO2008133952A3 (en) | Transmucosal treatment with fentanyl in patients with mucositis | |
| MX2007014803A (es) | Composiciones que penetran el nucleo celular. | |
| ZA200608865B (en) | Biologically active peptide VAPEEHPTLLTEAPLNPK derivatives | |
| TW200611696A (en) | Effervescent oral fentanyl dosage form and methods of administering fentanyl |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |